Oral Targeted Agent Recentin™ Active in Renal Cell Carcinoma - Cancer Consultants PDF Print
Cancer ConsultantsFinal results of a phase II randomised study of cediranib (Recentin™) in patients with advanced renal cell carcinoma (RCC). European Journal of Cancer

... read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.